Addex Therapeutics (ADXN) Common Equity (2022 - 2025)
Historic Common Equity for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to $7.4 million.
- Addex Therapeutics' Common Equity fell 4166.22% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year decrease of 4166.22%. This contributed to the annual value of $11.0 million for FY2024, which is 76248.09% up from last year.
- As of Q3 2025, Addex Therapeutics' Common Equity stood at $7.4 million, which was down 4166.22% from $8.7 million recorded in Q2 2025.
- In the past 5 years, Addex Therapeutics' Common Equity ranged from a high of $14.0 million in Q1 2022 and a low of -$1.6 million during Q1 2024
- Its 4-year average for Common Equity is $7.5 million, with a median of $7.4 million in 2025.
- Over the last 5 years, Addex Therapeutics' Common Equity had its largest YoY gain of 75545.03% in 2024, and its largest YoY loss of 13573.67% in 2024.
- Quarter analysis of 4 years shows Addex Therapeutics' Common Equity stood at $5.1 million in 2022, then crashed by 74.68% to $1.3 million in 2023, then skyrocketed by 755.45% to $11.0 million in 2024, then tumbled by 32.57% to $7.4 million in 2025.
- Its Common Equity stands at $7.4 million for Q3 2025, versus $8.7 million for Q2 2025 and $9.2 million for Q1 2025.